KPF
ESLA icon

K2 Principal Fund’s Estrella Immunopharma ESLA Stock Holding History

K2 Principal Fund’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-287,894
Closed -$2.85M – 388
2021
Q3 		$2.85M Buy
+287,894
New +$2.83M 0.23% 114

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

K2 Principal Fund's ESLA Position: Q4 2021 in Review

K2 Principal Fund sold out of Estrella Immunopharma (ESLA) in Q4 2021, closing a stake of 287,894 shares — an estimated $2.85M sold.

K2 Principal Fund first reported a position in ESLA in Q3 2021 and held it in 1 quarter. The position peaked at $2.85M in Q3 2021. 19 funds tracked by Wall St. Rank hold ESLA as of Q4 2021.

  • K2 Principal Fund reported no remaining Estrella Immunopharma position as of Q4 2021 after selling out during the quarter.
  • K2 Principal Fund sold 287,894 Estrella Immunopharma shares in Q4 2021, an estimated $2.85M.
  • K2 Principal Fund first reported a position in Estrella Immunopharma in Q3 2021 and held it in 1 quarter.
  • K2 Principal Fund's Estrella Immunopharma position peaked at $2.85M in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2021.

Based on K2 Principal Fund's 13F filing for Q4 2021, filed 11 Feb 2022.